Financials Zhejiang Xianju Pharmaceutical Co.,Ltd.

Equities

End-of-day quote Shenzhen S.E. Other stock markets 03:30:00 31/05/2024 am IST			5-day change	1st Jan Change
12.16 ^CNY	-0.82%		-1.94%	-4.78%

30/05	Zhejiang Xianju Pharmaceutical Co.,Ltd. Announces 2023 Final Profit Distribution on A Shares, Payable on 05 June 2024	CI
22/05	Zhejiang Xianju Pharmaceutical Co.,Ltd. Approves Cash Dividend for the Year 2023	CI

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Capitalization ¹	9,043	13,216	13,058	11,178	12,632	12,029	-	-
Enterprise Value (EV) ¹	9,043	13,216	13,058	11,178	12,632	12,029	12,029	12,029
P/E ratio	21.9 x	24.3 x	21.3 x	14.9 x	22.4 x	17.8 x	14.2 x	12 x
Yield	-	1.12%	1.14%	-	2.35%	1.97%	2.38%	-
Capitalization / Revenue	2.44 x	3.29 x	3.01 x	2.55 x	3.06 x	2.54 x	2.18 x	1.89 x
EV / Revenue	2.44 x	3.29 x	3.01 x	2.55 x	3.06 x	2.54 x	2.18 x	1.89 x
EV / EBITDA	13 x	17 x	13.8 x	10.5 x	14.7 x	12.4 x	10.3 x	8.71 x
EV / FCF	-	-	-	-	-	-	-	-
FCF Yield	-	-	-	-	-	-	-	-
Price to Book	3.07 x	2.97 x	2.7 x	2.05 x	2.18 x	1.93 x	1.75 x	1.6 x
Nbr of stocks (in thousands)	9,16,212	9,89,205	9,89,205	9,89,205	9,89,205	9,89,205	-	-
Reference price ²	9.870	13.36	13.20	11.30	12.77	12.16	12.16	12.16
Announcement Date	27/02/20	24/02/21	24/02/22	23/02/23	24/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net sales ¹	3,709	4,019	4,337	4,380	4,123	4,734	5,514	6,361
EBITDA ¹	693.4	777.5	943.2	1,069	860.2	966.3	1,165	1,381
EBIT ¹	543.4	597.2	754.7	878.6	646.5	795.9	997.3	1,175
Operating Margin	14.65%	14.86%	17.4%	20.06%	15.68%	16.81%	18.09%	18.46%
Earnings before Tax (EBT) ¹	527.3	621.2	725.9	871.9	641.7	790	991.3	1,168
Net income ¹	410.4	504.5	615.9	749.4	563.1	676.4	849.1	1,005
Net margin	11.07%	12.55%	14.2%	17.11%	13.66%	14.29%	15.4%	15.8%
EPS ²	0.4500	0.5500	0.6200	0.7576	0.5700	0.6840	0.8567	1.016
Free Cash Flow	-	-	-	-	-	-	-	-
FCF margin	-	-	-	-	-	-	-	-
FCF Conversion (EBITDA)	-	-	-	-	-	-	-	-
FCF Conversion (Net income)	-	-	-	-	-	-	-	-
Dividend per Share ²	-	0.1500	0.1500	-	0.3000	0.2400	0.2900	-
Announcement Date	27/02/20	24/02/21	24/02/22	23/02/23	24/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Fiscal Period: December	2019	2020	2021	2022	2023	2024	2025	2026
Net Debt	-	-	-	-	-	-	-	-
Net Cash position	-	-	-	-	-	-	-	-
Leverage (Debt/EBITDA)	-	-	-	-	-	-	-	-
Free Cash Flow	-	-	-	-	-	-	-	-
ROE (net income / shareholders' equity)	14.8%	15.5%	12.8%	14.6%	10.1%	10.9%	12.5%	13.3%
ROA (Net income/ Total Assets)	-	7.97%	8.99%	-	-	9%	10.3%	11.5%
Assets ¹	-	6,331	6,854	-	-	7,515	8,244	8,740
Book Value Per Share ²	3.210	4.490	4.880	5.520	5.850	6.300	6.940	7.610
Cash Flow per Share ²	0.5700	0.8000	0.6800	0.6200	0.6000	0.7900	0.9000	1.070
Capex ¹	255	117	229	279	233	221	263	241
Capex / Sales	6.87%	2.91%	5.28%	6.36%	5.66%	4.66%	4.77%	3.79%
Announcement Date	27/02/20	24/02/21	24/02/22	23/02/23	24/04/24	-	-	-

¹CNY in Million²CNY

Estimates

Trading Rating

Investor Rating

ESG Refinitiv

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

12.16 CNY

Average target price

15.21 CNY

Spread / Average Target

+25.08%

	1st Jan change	Capi.
ZHEJIANG XIANJU PHARMACEUTICAL CO.,LTD.	-4.78%	166.09Cr
ELI LILLY AND COMPANY	+40.73%	74TCr
NOVO NORDISK A/S	+32.83%	60TCr
JOHNSON & JOHNSON	-6.30%	35TCr
MERCK & CO., INC.	+15.15%	32TCr
ABBVIE INC.	+4.05%	28TCr
ASTRAZENECA PLC	+15.00%	24TCr
ROCHE HOLDING AG	-5.52%	21TCr
AMGEN INC.	+6.17%	16TCr
PFIZER, INC.	-0.45%	16TCr